Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Office: 4124 (B-stairs, 4th floor) ORCID identifier: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancerPP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers (2024)
- EMBO Molecular Medicine
(A1 Refereed original research article in a scientific journal) - Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth (2024)
- Cell Reports
(A1 Refereed original research article in a scientific journal) - Kun solujen kasvujarrut pettävät, syntyy syöpä - CIP2A:n tarina muutamasta peptidistä lääkekehitykseen (2024) Lääketieteen parantava voima - 100 tieteen tarinaa soluista sovelluksiin Westermarck, Jukka
(E1 Popularised article in a compilation book) - Suomen tieteen taso on jäänyt jälkeen kilpailijamaista (2024)
- Helsingin Sanomat
(Other publication) - The PP2A regulator IER5L supports prostate cancer progression (2024)
- Cell Death and Disease
(A1 Refereed original research article in a scientific journal) - ”Yliopistoista rahoituskriteerien perässä juoksevia tempputehtaita" – Opetusministeriön tiedepolitiikan virheitä ei saa toistaa tki-lisärahoituksen jaossa (2024)
- Kauppalehti
(E1 Popularised article) - CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response (2023)
- Trends in Cancer
(A2 Refereed review article in a scientific journal ) - Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition (2023)
- Cell ReportsEMBO Reports
(A1 Refereed original research article in a scientific journal) - Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma (2023)
- Molecular OncologyOral Oncology
(A2 Refereed review article in a scientific journal ) - Muutosneuvotteluiden jälkeen yliopiston fokus käännettävä tieteentekemisen edellytyksiin (2023)
- Turun Sanomat
(Other publication) - PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells (2023)
- Molecular Oncology
(A1 Refereed original research article in a scientific journal) - 2023
- Molecular Oncology
(A1 Refereed original research article in a scientific journal) - Protein phosphatase PP2A-based triple-strike therapy for medulloblastoma (2023)
- Molecular Oncology
(Other publication) - RAS and PP2A activities converge on epigenetic gene regulation (2023)
- Life Science Alliance
(A1 Refereed original research article in a scientific journal) - Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023)
- Nature Communications
(A1 Refereed original research article in a scientific journal) - Suomen TKI-politiikka ei tunnista terveystieteiden potentiaalia (2023)
- MustRead
(E1 Popularised article) - Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling (2022)
- Neurotherapeutics
(A1 Refereed original research article in a scientific journal) - CIP2A deficiency promotes depression-like behaviors in mice through inhibition of dendritic arborization (2022)
(A1 Refereed original research article in a scientific journal) - (2022)
(A1 Refereed original research article in a scientific journal) - Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells (2022)
- Scientific Reports
(A1 Refereed original research article in a scientific journal)